The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 521 million by 2031 with a CAGR of 3.3% during the forecast period 2025-2031.

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market

By 2025, the evolving U.S. tariff policy is poised to inject considerable uncertainty into the global economic landscape. This report delves into the latest U.S. tariff measures and the corresponding policy responses across the globe, evaluating their impacts on Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market competitiveness, regional economic performance, and supply chain configurations.

Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.

The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.

Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.

The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.

Market Segmentation

Scope of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Report

Report Metric	Details
Report Name	Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market
Forecasted market size in 2031	US$ 521 million
CAGR	3.3%
Forecasted years	2025 - 2031
By Type: (Dominant Segment vs High-Margin Innovation)	Live vaccines Inactivated vaccines
By Application: (Core Demand Driver vs Emerging Opportunity)	Government bidding Market sales
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company:	China Animal Husbandry Co., Ltd., Boehringer Ingelheim, MSD Animal Health, Sinopharm Animal Health, Ceva, Ruipu Biological, Qilu Animal Health, Dahuanong, CAVAC, Komipharm, Agrovet, Bioveta, Jinyu, Phibro Animal Health, Tiankang, Zoetis, Yongshun Biological, Pulike Biological
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Inactivated vaccines in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Market sales in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Live vaccines dominance in Europe vs. Inactivated vaccines demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

FAQ for this report

What is the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market size in 2031?

Ans: The Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market size in 2031 will be US$ 521 million.

Who are the main players in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market report?

Ans: The main players in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market are China Animal Husbandry Co., Ltd., Boehringer Ingelheim, MSD Animal Health, Sinopharm Animal Health, Ceva, Ruipu Biological, Qilu Animal Health, Dahuanong, CAVAC, Komipharm, Agrovet, Bioveta, Jinyu, Phibro Animal Health, Tiankang, Zoetis, Yongshun Biological, Pulike Biological

What are the Application segmentation covered in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market report?

Ans: The Applications covered in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market report are Government bidding, Market sales

What are the Type segmentation covered in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market report?

Ans: The Types covered in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market report are Live vaccines, Inactivated vaccines

1 Market Overview

1.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Scope

1.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Type

1.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020 & 2024 & 2031)

1.2.2 Live vaccines

1.2.3 Inactivated vaccines

1.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Application

1.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Comparison by Application (2020 & 2024 & 2031)

1.3.2 Government bidding

1.3.3 Market sales

1.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts (2020-2031)

1.4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size in Value Growth Rate (2020-2031)

1.4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size in Volume Growth Rate (2020-2031)

1.4.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Trends (2020-2031)

1.5 Assumptions and Limitations

2 Market Size and Prospective by Region

2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Region: 2020 VS 2024 VS 2031

2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Retrospective Market Scenario by Region (2020-2025)

2.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2020-2025)

2.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region (2020-2025)

2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts by Region (2026-2031)

2.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Estimates and Forecasts by Region (2026-2031)

2.3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Forecast by Region (2026-2031)

2.4 Major Region and Emerging Market Analysis

2.4.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)

2.4.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)

2.4.3 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)

2.4.4 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)

3 Global Market Size by Type

3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Historic Market Review by Type (2020-2025)

3.1.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025)

3.1.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (2020-2025)

3.1.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (2020-2025)

3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts by Type (2026-2031)

3.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Forecast by Type (2026-2031)

3.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Forecast by Type (2026-2031)

3.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Forecast by Type (2026-2031)

3.3 Different Types Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Representative Players

4 Global Market Size by Application

4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Historic Market Review by Application (2020-2025)

4.1.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025)

4.1.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (2020-2025)

4.1.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (2020-2025)

4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts by Application (2026-2031)

4.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Forecast by Application (2026-2031)

4.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Forecast by Application (2026-2031)

4.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Forecast by Application (2026-2031)

4.3 New Sources of Growth in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Application

5 Competition Landscape by Players

5.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Players (2020-2025)

5.2 Global Top Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players by Revenue (2020-2025)

5.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine as of 2024)

5.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Company (2020-2025)

5.5 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Manufacturing Sites & Headquarters

5.6 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Product Type & Application

5.7 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Date of Enter into This Industry

5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company

6.1.1.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)

6.1.1.2 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)

6.1.2 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)

6.1.3 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)

6.1.4 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer

6.1.5 North America Market Trend and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company

6.2.1.1 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)

6.2.1.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)

6.2.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)

6.2.3 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)

6.2.4 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer

6.2.5 Europe Market Trend and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company

6.3.1.1 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)

6.3.1.2 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)

6.3.2 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)

6.3.3 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)

6.3.4 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer

6.3.5 China Market Trend and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company

6.4.1.1 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)

6.4.1.2 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)

6.4.2 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)

6.4.3 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)

6.4.4 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer

6.4.5 Japan Market Trend and Opportunities

7 Company Profiles and Key Figures

7.1 China Animal Husbandry Co., Ltd.

7.1.1 China Animal Husbandry Co., Ltd. Company Information

7.1.2 China Animal Husbandry Co., Ltd. Business Overview

7.1.3 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.1.4 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.1.5 China Animal Husbandry Co., Ltd. Recent Development

7.2 Boehringer Ingelheim

7.2.1 Boehringer Ingelheim Company Information

7.2.2 Boehringer Ingelheim Business Overview

7.2.3 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.2.4 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.2.5 Boehringer Ingelheim Recent Development

7.3 MSD Animal Health

7.3.1 MSD Animal Health Company Information

7.3.2 MSD Animal Health Business Overview

7.3.3 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.3.4 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.3.5 MSD Animal Health Recent Development

7.4 Sinopharm Animal Health

7.4.1 Sinopharm Animal Health Company Information

7.4.2 Sinopharm Animal Health Business Overview

7.4.3 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.4.4 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.4.5 Sinopharm Animal Health Recent Development

7.5 Ceva

7.5.1 Ceva Company Information

7.5.2 Ceva Business Overview

7.5.3 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.5.4 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.5.5 Ceva Recent Development

7.6 Ruipu Biological

7.6.1 Ruipu Biological Company Information

7.6.2 Ruipu Biological Business Overview

7.6.3 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.6.4 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.6.5 Ruipu Biological Recent Development

7.7 Qilu Animal Health

7.7.1 Qilu Animal Health Company Information

7.7.2 Qilu Animal Health Business Overview

7.7.3 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.7.4 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.7.5 Qilu Animal Health Recent Development

7.8 Dahuanong

7.8.1 Dahuanong Company Information

7.8.2 Dahuanong Business Overview

7.8.3 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.8.4 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.8.5 Dahuanong Recent Development

7.9 CAVAC

7.9.1 CAVAC Company Information

7.9.2 CAVAC Business Overview

7.9.3 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.9.4 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.9.5 CAVAC Recent Development

7.10 Komipharm

7.10.1 Komipharm Company Information

7.10.2 Komipharm Business Overview

7.10.3 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.10.4 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.10.5 Komipharm Recent Development

7.11 Agrovet

7.11.1 Agrovet Company Information

7.11.2 Agrovet Business Overview

7.11.3 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.11.4 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.11.5 Agrovet Recent Development

7.12 Bioveta

7.12.1 Bioveta Company Information

7.12.2 Bioveta Business Overview

7.12.3 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.12.4 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.12.5 Bioveta Recent Development

7.13 Jinyu

7.13.1 Jinyu Company Information

7.13.2 Jinyu Business Overview

7.13.3 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.13.4 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.13.5 Jinyu Recent Development

7.14 Phibro Animal Health

7.14.1 Phibro Animal Health Company Information

7.14.2 Phibro Animal Health Business Overview

7.14.3 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.14.4 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.14.5 Phibro Animal Health Recent Development

7.15 Tiankang

7.15.1 Tiankang Company Information

7.15.2 Tiankang Business Overview

7.15.3 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.15.4 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.15.5 Tiankang Recent Development

7.16 Zoetis

7.16.1 Zoetis Company Information

7.16.2 Zoetis Business Overview

7.16.3 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.16.4 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.16.5 Zoetis Recent Development

7.17 Yongshun Biological

7.17.1 Yongshun Biological Company Information

7.17.2 Yongshun Biological Business Overview

7.17.3 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.17.4 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.17.5 Yongshun Biological Recent Development

7.18 Pulike Biological

7.18.1 Pulike Biological Company Information

7.18.2 Pulike Biological Business Overview

7.18.3 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)

7.18.4 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered

7.18.5 Pulike Biological Recent Development

8 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Manufacturing Cost Analysis

8.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

8.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

9.1 Marketing Channel

9.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors List

9.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers

10 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Dynamics

10.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Trends

10.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers

10.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges

10.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints

11 Research Findings and Conclusion

12 Appendix

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Author Details

12.3 Disclaimer

FEATURED COMPANIES

China Animal Husbandry Co. Ltd.

Boehringer Ingelheim

MSD Animal Health

Sinopharm Animal Health

List of Tables

Table 1. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)

Table 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)

Table 3. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) by Region (2020-2025)

Table 5. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2020-2025)

Table 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Market Share by Region (2020-2025)

Table 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Region (2020-2025)

Table 8. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Forecast by Region (2026-2031)

Table 9. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share Forecast by Region (2026-2031)

Table 10. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Forecast by Region (2026-2031)

Table 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share Forecast by Region (2026-2031)

Table 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (K Dose) & (2020-2025)

Table 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Type (2020-2025)

Table 14. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (US$ Million) & (2020-2025)

Table 15. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (US$/Dose) & (2020-2025)

Table 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (K Dose) & (2026-2031)

Table 17. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (US$ Million) & (2026-2031)

Table 18. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (US$/Dose) & (2026-2031)

Table 19. Representative Players of Each Type

Table 20. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (K Dose) & (2020-2025)

Table 21. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Application (2020-2025)

Table 22. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (US$ Million) & (2020-2025)

Table 23. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (US$/Dose) & (2020-2025)

Table 24. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (K Dose) & (2026-2031)

Table 25. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Application (US$ Million) & (2026-2031)

Table 26. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (US$/Dose) & (2026-2031)

Table 27. New Sources of Growth in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Application

Table 28. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (K Dose) & (2020-2025)

Table 29. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Company (2020-2025)

Table 30. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (US$ Million) & (2020-2025)

Table 31. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Company (2020-2025)

Table 32. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine as of 2024)

Table 33. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Company (US$/Dose) & (2020-2025)

Table 34. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Manufacturing Sites & Headquarters

Table 35. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Product Type & Application

Table 36. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Date of Enter into This Industry

Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 38. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)

Table 39. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)

Table 40. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)

Table 41. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)

Table 42. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)

Table 43. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)

Table 44. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)

Table 45. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)

Table 46. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)

Table 47. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)

Table 48. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)

Table 49. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)

Table 50. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)

Table 51. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)

Table 52. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)

Table 53. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)

Table 54. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)

Table 55. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)

Table 56. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)

Table 57. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)

Table 58. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)

Table 59. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)

Table 60. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)

Table 61. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)

Table 62. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)

Table 63. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)

Table 64. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)

Table 65. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)

Table 66. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)

Table 67. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)

Table 68. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)

Table 69. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)

Table 70. China Animal Husbandry Co., Ltd. Company Information

Table 71. China Animal Husbandry Co., Ltd. Description and Business Overview

Table 72. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 73. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 74. China Animal Husbandry Co., Ltd. Recent Development

Table 75. Boehringer Ingelheim Company Information

Table 76. Boehringer Ingelheim Description and Business Overview

Table 77. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 78. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 79. Boehringer Ingelheim Recent Development

Table 80. MSD Animal Health Company Information

Table 81. MSD Animal Health Description and Business Overview

Table 82. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 83. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 84. MSD Animal Health Recent Development

Table 85. Sinopharm Animal Health Company Information

Table 86. Sinopharm Animal Health Description and Business Overview

Table 87. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 88. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 89. Sinopharm Animal Health Recent Development

Table 90. Ceva Company Information

Table 91. Ceva Description and Business Overview

Table 92. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 93. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 94. Ceva Recent Development

Table 95. Ruipu Biological Company Information

Table 96. Ruipu Biological Description and Business Overview

Table 97. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 98. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 99. Ruipu Biological Recent Development

Table 100. Qilu Animal Health Company Information

Table 101. Qilu Animal Health Description and Business Overview

Table 102. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 103. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 104. Qilu Animal Health Recent Development

Table 105. Dahuanong Company Information

Table 106. Dahuanong Description and Business Overview

Table 107. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 108. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 109. Dahuanong Recent Development

Table 110. CAVAC Company Information

Table 111. CAVAC Description and Business Overview

Table 112. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 113. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 114. CAVAC Recent Development

Table 115. Komipharm Company Information

Table 116. Komipharm Description and Business Overview

Table 117. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 118. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 119. Komipharm Recent Development

Table 120. Agrovet Company Information

Table 121. Agrovet Description and Business Overview

Table 122. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 123. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 124. Agrovet Recent Development

Table 125. Bioveta Company Information

Table 126. Bioveta Description and Business Overview

Table 127. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 128. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 129. Bioveta Recent Development

Table 130. Jinyu Company Information

Table 131. Jinyu Description and Business Overview

Table 132. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 133. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 134. Jinyu Recent Development

Table 135. Phibro Animal Health Company Information

Table 136. Phibro Animal Health Description and Business Overview

Table 137. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 138. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 139. Phibro Animal Health Recent Development

Table 140. Tiankang Company Information

Table 141. Tiankang Description and Business Overview

Table 142. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 143. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 144. Tiankang Recent Development

Table 145. Zoetis Company Information

Table 146. Zoetis Description and Business Overview

Table 147. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 148. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 149. Zoetis Recent Development

Table 150. Yongshun Biological Company Information

Table 151. Yongshun Biological Description and Business Overview

Table 152. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 153. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 154. Yongshun Biological Recent Development

Table 155. Pulike Biological Company Information

Table 156. Pulike Biological Description and Business Overview

Table 157. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 158. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product

Table 159. Pulike Biological Recent Development

Table 160. Production Base and Market Concentration Rate of Raw Material

Table 161. Key Suppliers of Raw Materials

Table 162. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors List

Table 163. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers List

Table 164. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Trends

Table 165. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers

Table 166. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges

Table 167. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints

Table 168. Research Programs/Design for This Report

Table 169. Key Data Information from Secondary Sources

Table 170. Key Data Information from Primary Sources

List of Figures

Figure 1. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Picture

Figure 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) by Type (2020 & 2024 & 2031)

Figure 3. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type in 2024 & 2031

Figure 4. Live vaccines Product Picture

Figure 5. Inactivated vaccines Product Picture

Figure 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) by Application (2020 & 2024 & 2031)

Figure 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application in 2024 & 2031

Figure 8. Government bidding Examples

Figure 9. Market sales Examples

Figure 10. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Growth Rate (2020-2031) & (US$ Million)

Figure 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)

Figure 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Trends Growth Rate (2020-2031) & (US$/Dose)

Figure 14. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Report Years Considered

Figure 15. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Figure 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region: 2020 VS 2024

Figure 17. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)

Figure 19. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)

Figure 20. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)

Figure 21. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)

Figure 22. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)

Figure 23. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)

Figure 24. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)

Figure 25. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Type (2020-2025)

Figure 26. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Type (2026-2031)

Figure 27. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Type (2026-2031)

Figure 28. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Application (2020-2025)

Figure 29. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate by Application in 2020 & 2024

Figure 30. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Application (2026-2031)

Figure 31. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Application (2026-2031)

Figure 32. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Company (2024)

Figure 33. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Company (2024)

Figure 34. Global 5 Largest Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players Market Share by Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine: 2020 & 2024

Figure 35. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 36. Manufacturing Cost Structure of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

Figure 37. Manufacturing Process Analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

Figure 38. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industrial Chain

Figure 39. Channels of Distribution (Direct Vs Distribution)

Figure 40. Distributors Profiles

Figure 41. Bottom-up and Top-down Approaches for This Report

Figure 42. Data Triangulation

Figure 43. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4250

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$6000

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$8000

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions